Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
KZIA logo KZIA
Upturn stock ratingUpturn stock rating
KZIA logo

Kazia Therapeutics Ltd ADR (KZIA)

Upturn stock ratingUpturn stock rating
$6.27
Last Close (24-hour delay)
Profit since last BUY16.98%
upturn advisory
WEAK BUY
BUY since 18 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: KZIA (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $15.11

1 Year Target Price $15.11

Analysts Price Target For last 52 week
$15.11Target price
Low$2.86
Current$6.27
high$79

Analysis of Past Performance

Type Stock
Historic Profit -41.62%
Avg. Invested days 23
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 8.52M USD
Price to earnings Ratio -
1Y Target Price 15.11
Price to earnings Ratio -
1Y Target Price 15.11
Volume (30-day avg) 1
Beta 2.48
52 Weeks Range 2.86 - 79.00
Updated Date 06/30/2025
52 Weeks Range 2.86 - 79.00
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -29.15

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -42029.54%

Management Effectiveness

Return on Assets (TTM) -85.55%
Return on Equity (TTM) -3891.64%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 6699454
Price to Sales(TTM) 3.41
Enterprise Value 6699454
Price to Sales(TTM) 3.41
Enterprise Value to Revenue 4.43
Enterprise Value to EBITDA -0.71
Shares Outstanding 1359620
Shares Floating 422580635
Shares Outstanding 1359620
Shares Floating 422580635
Percent Insiders 10.09
Percent Institutions 8.22

Analyst Ratings

Rating 1
Target Price 15.11
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Kazia Therapeutics Ltd ADR

stock logo

Company Overview

overview logo History and Background

Kazia Therapeutics Ltd is an Australian oncology-focused drug development company, established in 2009. It focuses on developing novel therapies for cancer. Originally named Novogen, it rebranded to Kazia Therapeutics.

business area logo Core Business Areas

  • Oncology Drug Development: Focuses on developing and commercializing innovative therapies for cancer, with a pipeline of clinical and pre-clinical stage assets.

leadership logo Leadership and Structure

Kazia Therapeutics is led by a management team with experience in drug development and commercialization. The company has a board of directors providing oversight and guidance.

Top Products and Market Share

overview logo Key Offerings

  • Paxalisib: A PI3K/Akt/mTOR pathway inhibitor in clinical development for glioblastoma (GBM) and other cancers. While not yet approved and therefore having no revenue, competitors include Merck's Temodar, and other therapies used in GBM treatment.
  • Cantrixil: An oral formulation under evaluation in ovarian cancer. Phase 1 clinical trials have been completed. There are no revenue or users yet. Competitors include standard chemotherapy regimens for ovarian cancer.

Market Dynamics

industry overview logo Industry Overview

The oncology market is large and growing, driven by an aging population and advancements in cancer diagnostics and treatment. There's high demand for novel therapies with improved efficacy and safety profiles.

Positioning

Kazia Therapeutics is a small-cap biotech company focused on niche oncology markets. Its competitive advantage lies in its targeted therapies and clinical development expertise.

Total Addressable Market (TAM)

The global glioblastoma market is estimated at billions of USD. Kazia's position is as a developer of a novel treatment option, aiming to capture a share of this large market.

Upturn SWOT Analysis

Strengths

  • Novel drug candidates with potential for clinical benefit
  • Experienced management team
  • Focus on specific cancer subtypes
  • Clinical data showing promise in specific cancer indications

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • Drug development is high-risk and time-consuming
  • Reliance on clinical trial success
  • Currently no approved products on the market

Opportunities

  • Potential for regulatory approval of Paxalisib and Cantrixil
  • Partnerships with larger pharmaceutical companies
  • Expansion into new cancer indications
  • Advancements in personalized medicine

Threats

  • Clinical trial failures
  • Competition from other cancer therapies
  • Regulatory hurdles
  • Intellectual property challenges

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • BMY
  • NVS

Competitive Landscape

Kazia Therapeutics competes with larger pharmaceutical companies in the oncology market. Its advantage lies in its niche focus and novel therapies, but it faces significant challenges in terms of resources and market access. Kazia currently has no approved drugs on the market and therefore no market share.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by clinical trial advancements and pipeline progress.

Future Projections: Future growth is highly dependent on the successful development and commercialization of Paxalisib and Cantrixil. Analyst estimates vary widely depending on clinical trial outcomes.

Recent Initiatives: Recent initiatives include advancing Paxalisib in clinical trials for GBM and exploring new indications. They are also continuing to advance Cantrixil in Ovarian Cancer.

Summary

Kazia Therapeutics is a development-stage biotech company with promising oncology assets, particularly Paxalisib. Their success hinges on clinical trial outcomes and regulatory approvals. While their market cap is currently low, they face significant competition and financial constraints. Positive clinical data could dramatically improve their prospects.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • Market research reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in biotech companies involves significant risks, including clinical trial failures and regulatory hurdles.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Kazia Therapeutics Ltd ADR

Exchange NASDAQ
Headquaters Sydney, NSW, Australia
IPO Launch date 1999-01-06
CEO, MD & Director Dr. John Edwin Friend II, M.D.
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.